<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Hemolytic_Uremic_Syndrome_For_DeNovo_Initial_Section_C_Criteria_Q5</name>
        <optionSourceResponseValue>true</optionSourceResponseValue>
        <questionText>Monitoring strategy after eculizumab withdrawal, at a minimum:
1. Twice weekly home urinalysis to detect proteinuria or hematuria, for 6 months
2. Weekly bloodwork evaluating hemolysis parameters and renal function, for 6 months
3. Ongoing investigations after 6 months should be based on clinical judgment
4. The above strategy should be individualized based on clinical judgement</questionText>
        <status>Active</status>
        <versionNumber>1</versionNumber>
    </assessmentQuestionVersion>
    <dataType>TextBlock</dataType>
    <developerName>Hemolytic_Uremic_Syndrome_For_DeNovo_Initial_Section_C_Criteria_Q5</developerName>
    <name>Hemolytic_Uremic_Syndrome_For_DeNovo_Initial_Section_C_Criteria_Q5</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
